• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过凝血酶生成试验和因子IX活性监测B型血友病患者每周一次的重组因子IX预防治疗。

Monitoring once-weekly recombinant factor IX prophylaxis in hemophilia B with thrombin generation assay and factor IX activity.

作者信息

Nummi V, Jouppila A, Lassila R

机构信息

Faculty of Medicine, University of Helsinki, Helsinki, Finland.

Coagulation Disorders Unit, Department of Hematology and Comprehensive Cancer Center, Laboratory Services, Helsinki University Hospital, Helsinki, Finland.

出版信息

Int J Lab Hematol. 2017 Aug;39(4):359-368. doi: 10.1111/ijlh.12634. Epub 2017 Apr 13.

DOI:10.1111/ijlh.12634
PMID:28406575
Abstract

INTRODUCTION

Prophylaxis is the recommended treatment mode for severe hemophilia B. However, no single treatment regimen fits for all patients. Once-weekly prophylaxis with high-dose recombinant factor IX (rFIX) is efficacious, nevertheless, laboratory outcomes following 72 h after administration are lacking.

METHODS

In a prospective open-label noncomparative study, 10 severe/moderate (FIX ≤2 IU/dL) adult patients received rFIX dose (60-100 IU/kg) after >72 h washout on two occasions, separated by 7 days. We measured one-stage and chromogenic FIX, ROTEM, and thrombin generation (TG) assay in plasma after washout, 30 min after infusion, and at days 3, 4, and 7.

RESULTS

Median FIX clotting/chromogenic activity increased from 1.5/2.0 to 87/62 IU/dL following rFIX administration, chromogenic assay resulting in 30% lower recovery. Correspondingly TG was severely reduced at baseline and improved at recovery (peak thrombin 6.0 to 54 nm). Standard ROTEM failed to detect FIX deficiency. Both FIX activity and TG remained increased from days 3 to 7, with median trough levels of FIX clotting/chromogenic 3.0/3.0 IU/dL (≥1 IU/dL in all severe patients) and peak thrombin 9.1 nm measured on day 7. FIX and TG assays were equally consistent between weeks 1 and 2.

CONCLUSIONS

Once-weekly rFIX prophylaxis results in favorable laboratory outcome.

摘要

引言

预防是重度乙型血友病推荐的治疗模式。然而,没有一种单一的治疗方案适用于所有患者。高剂量重组凝血因子IX(rFIX)每周一次的预防方案是有效的,不过给药后72小时后的实验室结果尚缺乏。

方法

在一项前瞻性开放标签非对照研究中,10名重度/中度(FIX≤2IU/dL)成年患者在洗脱期>72小时后分两次接受rFIX剂量(60 - 100IU/kg),两次给药间隔7天。我们在洗脱后、输注后30分钟以及第3、4和7天测量血浆中的一期和发色底物法FIX、血栓弹力图(ROTEM)以及凝血酶生成(TG)试验。

结果

给予rFIX后,FIX凝血/发色底物活性中位数从1.5/2.0 IU/dL增加至87/6IU/dL,发色底物法检测到的回收率低30%。相应地,TG在基线时严重降低,恢复时有所改善(凝血酶峰值从6.0到54nM)。标准ROTEM未能检测到FIX缺乏。从第3天到第7天,FIX活性和TG均持续升高,FIX凝血/发色底物活性的中位数谷值为3.0/3.0 IU/dL(所有重度患者均≥1IU/dL),第7天测得的凝血酶峰值为9.1nM。FIX和TG试验在第1周和第2周之间同样具有一致性。

结论

每周一次的rFIX预防方案可产生良好的实验室结果。

相似文献

1
Monitoring once-weekly recombinant factor IX prophylaxis in hemophilia B with thrombin generation assay and factor IX activity.通过凝血酶生成试验和因子IX活性监测B型血友病患者每周一次的重组因子IX预防治疗。
Int J Lab Hematol. 2017 Aug;39(4):359-368. doi: 10.1111/ijlh.12634. Epub 2017 Apr 13.
2
Pharmacodynamics of eftrenonacog-alfa (rFIX-Fc) in severe hemophilia B patients: A real-life study.依非络靶(rFIX-Fc)在重度乙型血友病患者中的药效动力学:一项真实世界研究。
Eur J Pharmacol. 2021 Jan 15;891:173764. doi: 10.1016/j.ejphar.2020.173764. Epub 2020 Nov 27.
3
Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity.一种具有增强的体外和体内凝血活性的新型人重组凝血因子IX分子的表达与特性分析
Thromb Res. 2015 May;135(5):1017-24. doi: 10.1016/j.thromres.2015.02.034. Epub 2015 Mar 10.
4
Measuring factor IX activity of nonacog beta pegol with commercially available one-stage clotting and chromogenic assay kits: a two-center study.用市售的一步法凝固和显色测定试剂盒测定非活化因子 IX 聚乙二醇的因子 IX 活性:一项双中心研究。
J Thromb Haemost. 2016 Jul;14(7):1428-35. doi: 10.1111/jth.13348. Epub 2016 Jun 13.
5
Pharmacokinetic and pharmacodynamic properties of plasma-derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study.血浆源性与重组因子 IX 在乙型血友病患者中的药代动力学和药效学特性:一项前瞻性交叉研究。
J Thromb Haemost. 2014 Dec;12(12):2044-8. doi: 10.1111/jth.12756. Epub 2014 Nov 11.
6
Recombinant factor IX: discrepancies between one-stage clotting and chromogenic assays.重组凝血因子IX:一期凝血试验与发色底物法检测结果的差异
Haemophilia. 2014 Nov;20(6):891-7. doi: 10.1111/hae.12449. Epub 2014 May 7.
7
Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B.中重度至重度B型血友病患者接受每周一次的非阿可法α预防性治疗与按需治疗的对比
Haemophilia. 2016 May;22(3):381-8. doi: 10.1111/hae.12878. Epub 2016 Jan 29.
8
Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice.重组因子IX Fc融合蛋白维持完整的促凝血特性,并在血友病B小鼠中展现出延长的疗效。
PLoS One. 2016 Feb 3;11(2):e0148255. doi: 10.1371/journal.pone.0148255. eCollection 2016.
9
Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B.BAX326 的药代动力学、疗效和安全性:一项前瞻性、对照、多中心的 I/III 期研究,评估了先前接受治疗的重度(FIX 水平 <1%)或中度重度(FIX 水平 ≤2%)血友病 B 患者使用新型重组因子 IX BAX326 的效果。
Haemophilia. 2014 Jan;20(1):15-24. doi: 10.1111/hae.12228. Epub 2013 Jul 9.
10
In vivo efficacy of human recombinant factor IX produced by the human hepatoma cell line HuH-7.人肝癌细胞系HuH-7产生的重组人凝血因子IX的体内疗效
Haemophilia. 2015 Jul;21(4):e317-21. doi: 10.1111/hae.12688. Epub 2015 May 15.